NBTX trades 2.1% above Wall Street's consensus target of $38.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes NBTX achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 4 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of July 8, 2026, Nanobiotix S.A. (NBTX) has a Wall Street consensus price target of $38.00, based on estimates from 4 covering analysts. With the stock currently trading at $38.80, this represents a potential downside of -2.1%. The company has a market capitalization of $1.96B.
Analyst price targets range from a low of $30.00 to a high of $46.00, representing a 42% spread in expectations. The median target of $38.00 aligns closely with the consensus average.
The current analyst consensus rating is Buy, with 3 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, NBTX trades at a trailing P/E of -68.1x. Analysts expect EPS to grow +89.8% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
NVCRNovoCure Limited | $2.0B | $17.72 | $33.00 | +86.2% | Buy | — | 15 |
ARAYAccuray Incorporated | $30M | $0.25 | — | — | — | — | — |
SENSSenseonics Holdings, Inc. | $223M | $5.33 | $11.00 | +106.4% | Buy | — | 16 |
ONCOOnconetix, Inc. | $672525 | $1.07 | — | — | — | — | — |
CELCCelcuity Inc. | $5.6B | $115.72 | $153.22 | +32.4% | Buy | — | 12 |
AGENAgenus Inc. | $146M | $3.50 | $7.33 | +109.4% | Buy | 4.5x | 11 |
IMVTImmunovant, Inc. | $8.2B | $40.09 | $45.00 | +12.2% | Buy | — | 23 |
CLDXCelldex Therapeutics, Inc. | $2.7B | $39.93 | $49.00 | +22.7% | Buy | — | 19 |
NKTRNektar Therapeutics | $1.5B | $74.90 | $149.60 | +99.7% | Buy | — | 33 |
HALOHalozyme Therapeutics, Inc. | $9.7B | $81.57 | $88.25 | +8.2% | Buy | 10.1x | 27 |
Quick answers to the most common questions about buying NBTX stock.
Wall Street's consensus price target for NBTX is $38, -2.1% from its current price of $38.8. The below-market target from 4 analysts suggests limited near-term appreciation.
NBTX has a consensus rating of "Buy" based on 4 Wall Street analysts. The rating breakdown is predominantly bullish, with 3 Buy/Strong Buy ratings. The consensus 12-month price target of $38 implies -2.1% downside from current levels.
NBTX's current price is $38.8 with a consensus target of $38 (-2.1% implied move). Analyst estimates suggest the stock is fairly valued at current levels.
The most bullish Wall Street analyst has a price target of $46 for NBTX, while the most conservative target is $30. The consensus of $38 represents the median expectation. These targets typically reflect 12-month expectations.
NBTX is lightly followed, with 4 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 3 have Buy ratings, 1 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month NBTX stock forecast based on 4 Wall Street analysts shows a consensus price target of $38, with estimates ranging from $30 (bear case) to $46 (bull case). The median consensus rating is "Buy".
Analysts are cautious on NBTX, with 0 Sell ratings and a price target of $38 (-2.1% from current price). The "Buy" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
NBTX analyst price targets range from $30 to $46, a 42% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $38 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.